Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT05140746

Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

Led by Ruijin Hospital · Updated on 2024-01-09

40

Participants Needed

1

Research Sites

365 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation of treatment response to neoadjuvant chemotherapy(NAC) for patients with locally advanced gastric cancer(LAGC).

CONDITIONS

Official Title

Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18-75 years.
  • Histologically confirmed gastric adenocarcinoma through gastroscopy.
  • Resectable gastric cancer.
  • ECOG performance status 0-1.
  • White blood count >4x10^9/L, Absolute neutrophil count (ANC) >2x10^9/L, Hemoglobin (Hb) >90g/L, Platelets >100x10^9/L.
  • Ejection fraction >50%.
  • Serum bilirubin <1.5 times upper limit of normal (ULN); ALT and AST <1.5 times ULN.
  • Serum creatinine ≤1.5 times ULN, or glomerular filtration rate (GFR) >60 ml/min.
  • Agreement to participate in this study with informed consent form.
  • Willingness and ability to comply with the protocol for the duration of the study.
  • No children bearing potential in the next six months before enrollment.
Not Eligible

You will not qualify if you...

  • Having second primary malignant diseases in past five years, except cured basal cell and squamous cell carcinoma of the skin.
  • Known hypersensitivity reaction to chemotherapy drugs or contraindications to chemotherapy.
  • Severe disease or other unsuitable conditions as determined by investigators, including inadequate organ function.
  • Uncontrollable diabetes or fasting blood glucose level ≥11 mmol/L on test day.
  • Severe mental symptoms, unconsciousness, or inability to complete the examination.
  • Pregnancy, possible pregnancy, or breastfeeding.
  • Lack of compliance with study requirements.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Ruijin Hospital

Shanghai, Shanghai Municipality, China, 200025

Actively Recruiting

Loading map...

Research Team

Y

Ying Miao

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here